Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis

European Journal of Haematology

Volumn 62, Issue 2, 1999, Pages 90-94

  Dar, Saleem ^a   Mundle, Suneel ^a   Andric, Tanja ^a   Qawi, Huma ^a   Shetty, Vilasini ^a   Reza, Samina ^a   Mativi, B Yifwayimare ^a   Allampallam, Krishnan ^a   Ali, Ambereen ^a   Venugopal, Parameswaren ^a   Gezer, Sefer ^a   Broady Robinson, LaTanya ^a   Cartlidge, John ^a   Showel, Margaret ^a   Hussaini, Seema ^a   Ragasa, Deborah ^a   Ali, Irfan ^a   Chaudhry, Ambreen ^a   Waggoner, Samina ^a   Lisak, Laurie ^a   Huang, Ray Win ^a   Raza, Azra ^a   more..

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bone marrow; Human disease; In vivo; Macrophage; Myelodysplastic syndromes (MDS); Proliferation; Tumor necrosis factor (TNF )

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; DNA DAMAGE; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

EID: 0032933930     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01727.x     Document Type: Article

References (13)

1. CLARK DM, LAMPERT IA. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective hematopoiesis. Leuk Lymph 1990;2:415-418.
2. YOSHIDA Y. Apoptosis may be the mechanism responsible for the premature intramedullary cell death in myelodysplastic syndromes. Leukemia 1993;7:144-146.
3. RAZA A, MUNDLE S, IFTIKHAR A, et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hemat 1995;48:143-154.
4. RAZA A, GEZER S, MUNDLE S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-276.
5. HATFILL SJ, FESTER ED, STEYTLER JG. Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes. Hematol Pathol 1992;6:87-93.
6. BOWEN D. What is ineffective erythropoiesis in myelodysplastic syndromes? Leuk Lymp 1995;18:243-247.
7. BAGBY JR GC. Mechanisms of glucocorticoid activity in patients with pre-leukemia syndromes (hematopoietic dysplasia). Leuk Res 1980;4:571-580.
8. RAZA A, VENUGOPAL P, GEZER S, et al. Pilot study of pentoxifylline and ciprofloxacin with or without dexamenthasone produces encouraging results in myelodysplastic syndromes In: HIDDENMANN W, BUCHNER T, WORMANN B, et al, eds. Acute leukemias. VII Experimental approaches and novel therapies, vol. 39. Springer-Verlag: Berlin, 1998:42-51.
9. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
10. RAZA A, MUNDLE S, SHETTY V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoplosis and the role of cytokines. Int J Hematol 1996;63:265-278.
11. IRVINE AE, MAGILL MK, SOMERVILLE, McMULLIN MF. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp Hematol 1998;26:435-439.
12. RAJAPAKSA R, GINZTON N, ROTT LS, et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275-4287.
13. SHETTY V, MUNDLE S, ALVI S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20:891-900.